Integration of CAR-T Therapies into Clinical Practice: Mechanism, Specialized Centers, and Future in Spain
Advanced CAR-T therapies have revolutionized the treatment of certain hematologic cancers. This approach, which combines cutting-edge biomedical knowledge with advanced therapies, offers a highly personalized alternative with remarkable efficacy rates in patients.
In Spain, the expansion of specialized centers for advanced therapies is accelerating, with regulations and access plans aiming to make these treatments widely available.
How Do CAR-T Advanced Therapies Work and When Are They Used?
CAR-T therapies modify a patient’s immune system, enabling it to recognize, attack, and eliminate cancer cells. These therapies rely on the genetic modification of the patient’s T lymphocytes to express a receptor on their surface that can detect and destroy tumor cells. This receptor, known as a Chimeric Antigen Receptor (CAR), allows T cells to act with high specificity, bypassing the conventional antigen presentation process mediated by the major histocompatibility complex. Figure 1 describes the process in detail.

Figure 1. Process of Chimeric Antigen Receptor (CAR) T-Cell Therapy. 1) T cells are extracted from the patient’s blood. 2) In the laboratory, the gene encoding specific antigen receptors is introduced into the T cells. 3) This results in the production of CAR receptors on the cell surface. 4) The newly modified T cells are harvested and cultured in the laboratory. 5) After a certain period, the modified T cells are reinfused into the patient.
The application of these advanced therapies has demonstrated significant efficacy in hematologic tumors. Between 80-90% of patients with acute lymphoblastic leukemia achieve durable remission or complete recovery following CAR-T cell therapy. For patients with B-cell non-Hodgkin lymphoma, the response rate ranges from 40-60%.
The use of CAR-T therapies in solid tumors remains a challenge due to antigenic diversity, an immunosuppressive microenvironment, and difficulties in achieving sufficient proliferation and infiltration. However, preliminary clinical trial data indicate some therapeutic efficacy of CAR-T cells in neuroblastoma, prostate cancer, and soft tissue sarcoma.
Specialized Centers for Advanced Therapies in Spain: Where Are CAR-T Treatments Administered?
Spain’s National Health System (SNS) has established the Advanced Therapies Strategy, driven by the Ministry of Health, to ensure equitable and safe access to CAR-T therapies. This initiative defines patient selection criteria, finances treatments within the SNS, and regulates the distribution of these therapies in accredited hospital centers.
The implementation of CAR-T treatments has been made possible through a network of accredited advanced therapy centers. Leading hospitals in Spain offering CAR-T therapy include Hospital Clínic de Barcelona, Hospital Universitario La Paz in Madrid, and Hospital Virgen del Rocío in Seville, among others.

Currently, Spain has 28 accredited centers managing these advanced therapies, though expansion plans are underway to ensure broader accessibility. In September 2024, the Ministry announced the convening of a technical committee for the Advanced Therapies Strategy to update and refine the plan, aiming to expand the network and incorporate new therapies.
The full list of accredited hospital centers is available on the Ministry of Health’s website.
Spain’s Advanced Therapies Plan: Regulation, Access, and the Future of CAR-T Treatment
The first CAR-T therapy was integrated into Spain’s National Health System in 2018. To date, four industrially manufactured CAR-T treatments and one non-industrial therapy, ARI-0001, have been approved.
Since the launch of the Advanced Therapies Strategy in 2018, over 1,406 patients have received CAR-T treatment. Access to these therapies remains highly regulated, requiring multidisciplinary committee evaluations for each case.
A breakthrough in Spain is the ability of certain public hospitals to develop their own CAR-T therapies, reducing reliance on commercial treatments and improving patient accessibility.
The Biomedical Research Institute August Pi i Sunyer (IDIBAPS) at Hospital Clínic de Barcelona pioneered the development of ARI-0001 for treating acute lymphoblastic leukemia in patients over 25. In February 2021, it became the first CAR-T therapy fully developed in Europe to receive authorization from a regulatory agency.
The same institute has also developed ARI-0002h for multiple myeloma, which received approval from the Spanish Agency for Medicines and Medical Devices (AEMPS) in July 2024.
Developing CAR-T therapies in hospital centers reduces costs by over 75%. The latest CAR-T treatments approved by the European Medicines Agency cost around €400,000 per patient, whereas ARI-0001 is priced below €90,000.
Specialized Solutions for CAR-T Therapies
The success of CAR-T therapies relies on an integrated system that ensures the viability of T lymphocytes from initial storage to patient infusion. At Bexen Bioservices, we provide solutions for sample preservation and cell performance, including ultra-freezing equipment, controlled thawing systems, and filling systems.
We operate private biorepositories spanning 360 m², designed for ultra-low-temperature storage to maintain optimal sample preservation.
Visit our website for more information.
References
- Del Castillo M. El gran logro científico de la sanidad pública: hospitales capaces de producir sus propios CAR-T contra el cáncer [Internet]. El País; 2024 Nov 9 [cited 20 Feb 2025]. Available from: https://elpais.com/sociedad/2024-11-09/el-gran-logro-cientifico-de-la-sanidad-publica-hospitales-capaces-de-producir-sus-propios-car-t-contra-el-cancer.html
- Gobierno de España. La Moncloa. El Gobierno impulsa un plan para potenciar las terapias avanzadas y la fabricación de medicamentos estratégicos en España [Internet]. Madrid: La Moncloa; 2024 [cited 20 Feb 2025]. Available from: https://www.lamoncloa.gob.es/serviciosdeprensa/notasprensa/sanidad14/paginas/2024/230924-terapias-avanzadas.aspx
- Lin H, Cheng J, Mu W, Zhou J, Zhu L. Advances in Universal CAR-T Cell Therapy. Front Immunol. 2021 Oct 6;12:744823. doi: 10.3389/fimmu.2021.744823.
- Ministerio de Sanidad (España). Terapias avanzadas [Internet]. Madrid: Ministerio de Sanidad; [cited 20 Feb 2025]. Available from: https://www.sanidad.gob.es/areas/farmacia/infoMedicamentos/terapiasAvanzadas/home.htm
- Sun D, Shi X, Li S, Wang X, Yang X, Wan M. CAR-T cell therapy: A breakthrough in traditional cancer treatment strategies (Review). Mol Med Rep. 2024 Mar;29(3):47. doi: 10.3892/mmr.2024.13171.